Etoposide, Dexamethasone, and Pegaspargase with Sandwiched Radiotherapy in Early-Stage Natural Killer/t-Cell Lymphoma: A Randomized Phase III Study.
Huijuan Zhong,Shu Cheng,Xi Zhang,Bing Xu,Jiayi Chen,Xufeng Jiang,Jie Xiong,Yu Hu,Guohui Cui,Juying Wei,Wenbin Qian,Xiaobing Huang,Ming Hou,Feng Yan,Xin Wang,Yongping Song,Jianda Hu,Yuanhua Liu,Xuejun Ma,Fei Li,Chongyang Wu,Junmin Chen,Li Yu,Ou Bai,Jingyan Xu,Zunmin Zhu,Li Liu,Xin Zhou,Li Huang,Yin Tong,Ting Niu,Depei Wu,Hao Zhang,Chaofu Wang,Binshen Ouyang,Hongmei Yi,Qi Song,Gang Cai,Biao Li,Jia Liu,Zhifeng Li,Rong Xiao,Luqun Wang,Yujie Jiang,Yanyan Liu,Xiaoyun Zheng,Pengpeng Xu,Hengye Huang,Li Wang,Saijuan Chen,Weili Zhao
DOI: https://doi.org/10.1016/j.xinn.2023.100426
2023-01-01
Abstract:Methotrexate, etoposide, dexamethasone, and pegaspargase (MESA) with sandwiched radiotherapy is known to be effective for early-stage extranodal natural killer/T-cell lymphoma, nasal type (NKTCL). We explored the efficacy and safety of reduced-intensity, non-intravenous etoposide, dexamethasone, and pegaspargase (ESA) with sandwiched radiotherapy. This multicenter, randomized, phase III trial enrolled pa-tients aged between 14 and 70 years with newly diagnosed early-stage nasal NKTCL from 27 centers in China. Patients were randomly as-signed (1:1) to receive ESA (pegaspargase 2,500 IU/m2 intramuscularly on day 1, etoposide 200 mg orally, and dexamethasone 40 mg orally on days 2-4) or MESA (methotrexate 1 g/m2 intravenously on day 1, eto-poside 200 mg orally, and dexamethasone 40 mg orally on days 2-4, and pegaspargase 2,500 IU/m2 intramuscularly on day 5) regimen (four cycles), combined with sandwiched radiotherapy. The primaryendpoint was overall response rate (ORR). The non-inferiority margin was-10.0%. From March 16, 2016, to July 17, 2020, 256 patients un-derwent randomization, and 248 (ESA [n = 125] or MESA [n = 123]) made up the modified intention-to-treat population. The ORR was 88.8% (95% confidence interval [CI], 81.9-93.7) for ESA with sand-wiched radiotherapy and 86.2% (95% CI, 78.8-91.7) for MESA with sandwiched radiotherapy, with an absolute rate difference of 2.6% (95% CI,-5.6-10.9), meeting the non-inferiority criteria. Per-protocol and sensitivity analysis supported this result. Adverse events of grade 3 or higher occurred in 42 (33.6%) patients in the ESA arm and 81 (65.9%) in the MESA arm. ESA with sandwiched radiotherapy is an effective, low toxicity, non-intravenous regimen with an outpatient design, and can be considered as a first-line treatment option in newly diagnosed early-stage nasal NKTCL.